Source R&D directory

Company ProďŹ les

R&D Finding your CRO/CMO partner

2015 Source R&D Directory - a new initiative from Source R&D

1

Company ProďŹ les

London’s premier Life Science & Healthcare networking conference

genesis 2015 IFC 10 December 2015 Queen Elizabeth II Conference Centre Westminster, London, UK

genesisconference.com 2

Source R&D

Company Profiles Contents

4

R&D Outsourcing

Tony Jones of One Nucleus, Geoff Lawton of INMedD and Chris Keep of AstraZeneca on the R&D outsourcing business environment

7

15

Company Profiles Abzena plc

7

AMS Biotechnology (Europe) Limited

8

Cambridge Research Biochemicals

8

Catalent Pharma Solutions

9

Evotec

10

Isogenica

12

New England Biolabs (UK) Ltd

13

Pathology Diagnostics Ltd

14

ProSynth Limited

14

Contact Information Listings for One Nucleus and Bionow CRO, CMO and service provider member companies Cover image from iStock.com © scanrail The Source R&D Directory is published on behalf of One Nucleus and Bionow by Hartswood Media, Hallmark House, 25 Downham Road, Ramsden Heath CM11 1PU, United Kingdom Tel: +44 (0)1277 211691 Email: paulbarrett@hartswoodmedia.com Printed by Manor Creative Ltd, Eastbourne, East Sussex, United Kingdom.

Source R&D

3

R&D Outsourcing Company Profiles

One Nucleus and the Source R&D Directory

T

he origins of the work One Nucleus has undertaken over the past year with regard to supporting the service provision cohort of our sector stem from a number of observations about our membership diversity and the changing industry landscape. There is also an apparent underestimation of the expertise, translational research competence and economic value of the service sector in various quarters.

The increasing externalisation and partnership approach to new medicine discovery means that any region may need to position itself as an outsourcing location of choice – not due to cost but due to provision of a highly connected drug discovery and development supply chain.

We have explored the changing role and challenges of the R&D service providers in the Life Sciences landscape. It is clear that many of the challenges are common across all service-based industries and are sector agnostic, such as the ‘them and us’

culture among clients and a feeling of supplying commoditised services and goods. The sector is believed to be worth an estimated $10 billion, with up to 500 CRO and CMO organisations in the UK, but there is a dearth of accurate and validated data to confirm this. A contributing factor in this is defining the R&D services sector given the diverse set of roles it encompasses along the drug discovery and development pipeline. Defining this sector, for example by company numbers, annual turnover or number of employees, is an important goal to attract more business and enable effective advocacy by the appropriate associations.

Increasing demand appears to be fuelled from the discovery, rather than development, stage of the R&D pipeline. This could be expected in light of the down-sizing of the pharmaceutical industry’s internal early-stage efforts, and the consequential need to invest in discovery via external contracts. Another factor is the increasing focus of venture funds on asset-centric

The role of CROs in the De-aggregated Biopharma system

T

he business environment in which new medicines are invented has been completely transformed in the past two decades.

Biopharma 1.0 had thrived for fifty years providing many new medicines and also good returns to investors. The vast majority of the work was carried out in fully integrated pharmaceutical companies (FIPCOs). These businesses owned the portfolio of projects and also owned the laboratory facilities where the operations were carried out by talented scientists employed by the FIPCO. Productivity in FIPCOs is now widely perceived to provide very poor return on research investment. Tomes have been written on the reasons for this decline, which are many and varied.

The large pharma companies have severely reduced their internal research investment and now increasingly look to a range of external providers to deliver their drug candidates. Biopharma 2.0 has evolved in response and is now becoming established. This is a much more diverse landscape where partnerships between different businesses are the norm. The many skills required for creating a new medicine can now be provided by separate specialist companies. Clinical research expertise was the first to be made available via contract arrangements. Today all of the many required drug discovery skills can be accessed through specialist providers.

Contract research organisations (CRO) are increasingly replacing FIPCOs as the largest repository of expertise in all aspects of drug discovery and development. For example, some large

4

Source R&D

pharma companies use CROs to provide almost all of their clinical development operations. The extent of the change with respect to chemistry was discussed by Chris Newton, Senior Vice President at Galapagos NV, in a recent presentation (RSC/SCI September 2014).

In the UK, his survey revealed that the number of drug discovery chemists employed by CROs is now more than 50% of the total.

Use of CROs allows separation of the ownership (and funding) of the project portfolio from the organisations operating the projects. The financial portfolio does not have to be the same as the operational portfolio. At one extreme, as was usual in Biopharma 1.0, the operator of a project portfolio would also be the funder/investor.

At the other extreme, the projects within the funded portfolio can each be managed virtually and operated by one or more CROs. Flexible control of financial commitments and more effective risk management are key advantages for investors in Biopharma 2.0.

CROs are critical to the future of medicine discovery. No aspect of the process is static and continuous development is essential.

Training, personal development and nurturing the skills was previously undertaken by FIPCOs. Who will be responsible in BioPharma 2.0?

For specialist technologies this is already largely in CROs. Many CROs are attractive to their clients because of their technical expertise. The ability to focus on a single skill and provision to multiple clients allows them to develop critical mass and to become world leaders in their skill set. The more generic skills of project and

R&D Outsourcing Company Profiles investments and virtual biotech business models. There are challenges however, especially for the smaller companies supplying these R&D services. Sponsors are running much slimmer portfolios, resulting in fewer but larger projects that tend to be attractive to larger one-stop-shop style providers. In their competitive environment, there is significant pressure to reduce margins yet balance winning contracts with sustainability.

Furthermore, the procurement process and the key performance indicators attached to the role of purchasing officers within clients often squeeze the provider on price. A strategy ill-aligned with sustainability of the supplier. This can be exacerbated for SMEs when Government-supported new entrants with reduced or subsidised overheads can under-price projects whilst the larger providers have sufficiently strong balance sheets to offer lostleader bids.

Image has been a key element that has led One Nucleus to produce the Source R&D Directory. The contract sector suffers from something of an image and identity crisis - perhaps as a result of being under-valued by sponsors and policymakers as commodity rather than high-value-adding expertise. There are innumerable positioning terms used within the fee-for-service cohort, partly to address the above prejudices, but to also accurately reflect their often proprietary offer. The terminology

can include straight CRO and CMO, solution providers, R&D collaborators and many more, each with their own perfectly justified rationales for differentiation. A positive self-image is required that encompasses this diversity and collective excellence. One Nucleus has taken the initiative in correcting this image by showcasing the expertise and value-adding offer Tony Jones – Business Development from the service sector. The Director at One Nucleus Source R&D Directory is a vital part of the strategy, enabling clients, partners and policy makers to fully navigate and understand the manifold benefits of the R&D Services sector. We are delighted Bionow have joined us in supporting our respective providers in this inaugural publication of the Source R&D Directory with Hartswood Media.

portfolio management have so far mostly been retained by the funder. In the short term, management of virtual programmes has been directed by individuals who gained their expertise through years of exposure to drug discovery within FIPCOs and owing to the downsizing became available as consultants. These individuals have the tacit technical and process skills which are essential for making the critical decisions: which project, which technology, which outsource provider, which lead, which candidate, when to stop; and can provide effective management of the outsourced provisions.

Today there are many such individuals who learnt the skills in the FIPCOs where they were exposed to all of the very wide-ranging components of successful drug hunting.

BUT: where is the training ground for the next generation of drug hunters? Exposure to many successful and unsuccessful projects is a key component of the learning. Those CROs providing ‘integrated’ drug discovery ‘services’ have a great opportunity to effectively develop the high level skills and to be knowledge leaders.

Impediments including a heavy focus on cost-containment and the need for firewalls between projects will need to be overcome.

CROs are a key component of the future system. Many business models are available.

A pure fee-for-service company generates experimental data and the rights to this IP are wholly owned by the client. The range of providers includes those that carry out experiments to the client’s design through to those that provide all of the design, the client simply providing the funding and cost control. All of the many facets of drug discovery from target discovery through candidate identification and clinical development can be sourced from this type of business structure. Some providers can offer a ‘one-stop shop’, while others provide only single skill sets and the client puts together a supply chain of providers. A growing number of CROs fall into a

hybrid category where they are prepared to assume a share of the risk in return for appropriate reward for success.

As the BioPharma system continues to dis-aggregate, a range of different investor types can be accommodated within one operational portfolio and conversely, a single funder can carry out its projects in different operational business structures. There is now increasing recognition Geoff Lawton – consultant, founder of INMedD that partnerships between different stakeholders are essential in the new landscape of Biopharma 2.0. At present the partnerships are usually formed and controlled by large pharma companies (FIPNET). Almost all big pharma companies now advertise themselves as the hub of a network of partnerships and collaborations. It is likely that the drivers of future partnerships will include a wider spectrum of stakeholders. These will include venture philanthropists, medical insurance companies and governments.

We are already seeing the emergence of, for example, The Wellcome Trust, Bill & Melinda Gates Foundation, Michael J Fox and Cystic Fibrosis Foundation using their power to bring together the components of the supply chain. CROs are a critical component of this evolving system.

Source R&D

5

R&D Outsourcing Company Profiles

The ‘Delivery Marketplace’ we are working in Pharma, CROs and AROs working together…

I

ncreasingly we are working in a world of multiple delivery models and many external suppliers, collaborators and partners.

Being a supplier, a partner and a collaborator is not easy and requires significant effort in many areas beyond simply delivering the contracted scientific/clinical outputs; these include reducing delivery lead times; increasing cost efficiency and actively managing the business relationships with pharma sponsors.

A variety of delivery models and approaches are used with pharma organisations, with companies often moving between models over time. We are not seeing one approach as being significantly better than another; instead we see that tailoring the solution to the client’s requirement is becoming more important. Regardless of the approach adopted, the key is commitment and support to execute well, dealing with issues that inevitably come up rather than losing faith in earlier decisions.

In addition to the classical CRO (Contract or, to some, Clinical Research Organisation), there also exists the ARO (Academic Research Organisation). The latter, often associated with universities, hospitals, charities and other not-for-profit institutions, are also playing an increasing role in clinical development and occasionally competing with the CROs. In our experience the many differences between these two distinct types of partner requires a more tailored approach.

Contract Research Organisations The CRO industry is maturing with continued consolidation resulting in global suppliers emerging. These suppliers are creating tailored and fullservice delivery solutions for their pharma sponsors and as such several sponsors have subsequently formed closer relationships/partnerships with preferred supplier CROs. Pharma will continue to maintain preferred relationships with a small number CRO partners who share a vision for ‘performance based partnership’, with these relationships only realising their full potential where objectives are aligned, where there is continued investment on both sides and ultimately mutual benefit.

The essential characteristics of successful CRO/pharma partnerships are: • High levels of trust, with clear accountability for quality, delivery and cost and increased openness and commercial transparency • Customer preference, with CROs adopting a differentiated approach to their most important customers, for example providing their most experienced and capable resources or granting early access to innovation • Sustained performance over time, driven by continuous improvement, simplification and technology enablement • Shared culture of collaboration, focusing on the partner’s needs and acting upon feedback For the CROs, the benefits are multiple and can include: • Increased share of the sponsor’s business • Improved revenues and margins through shared efficiency gains • Longer-term agreements • Deeper relationships with their sponsors 6

Source R&D

Academic Research Organisations (AROs) and Collaborative Groups (CGs) The driver for these groups is scientific leadership.

For the sponsor, AROs and CGs offer unique capabilities.

Working in this type of relationship often requires greater adaptability from both parties in order to work successfully together, particularly Chris Keep of in the business contractual relationship. Some AstraZeneca reasons for this include: • AROs and CGs don’t always see the similarities that they have with CROs even though some aspects of the delivery models are common • Their geographic footprint is predominantly regional and rarely global • In some cases their business models and practices are less mature than those of pharma companies and CROs, with fewer experienced business people allocated to developing scope, budgets, terms & conditions and compliance processes • They may find it more difficult to provide the increasing transparency reporting expected of pharma companies in dealing with HCPs and Healthcare Institutions (eg US Open Payments, Fair Market Value, ABAC) • Greater overhead charges on top of professional fee costs vary.

Owing to some of the gaps in capability sometimes a hybrid ARO-CRO delivery model is required, particularly for large-scale clinical trials.

Clearly one size does not fit all with AROs and CGs, and consequently the sponsor needs to consider the relative balance between scientific leadership, delivery risk and cost when considering a relationship with an ARO or CG. Employing some simple ‘rules’ can often help: • Operationally: • Try to minimise the size of the pharma company’s internal team that interacts with the ARO or CG on a day-to-day basis with clearly defined core team roles and single points of contact • Use common tools or processes with emphasis on efficiency and cost effectiveness • Set clear expectations on the use of established preferred suppliers for core enabling services while considering the benefit of using an ARO or GC’s partner • Culturally: • Enter the relationship with the right mindset – adopting a ‘ learner’ frame of reference versus that of a ‘knower’ ensures curious, constructive conversations and helps to build trust, resulting in the development of new ways to work together more effectively • Demonstrate ‘integrative thinking’, understand the interdependencies and dealing with complex aspects while keeping sight of the bigger picture • Find solutions that don’t force choices between options which appear to be mutually exclusive Chris Keep is Global Category Leader, Academic & Healthcare Professionals Services, GMD Procurement at AstraZeneca based in Macclesfield, United Kingdom.

Tel: +44 (0)1625 513718 Email: chris.keep@astrazeneca.com

Company Profiles

A

bzena provides a suite of complementary services and technologies to R&D organisations to select and create better therapeutic proteins and antibodies with less risk of failure in clinical development and it is therefore poised to capitalise on the growth of the biopharmaceutical market. The Group’s technologies and services are provided through its wholly owned subsidiaries, PolyTherics and Antitope.

PolyTherics and Antitope have been developing and offering their technologies and services for over 10 years and their scientists have provided expertise to a wide range of companies, including most of the top 20 biopharmaceutical companies, many large and small public and private biotech, and academic groups, across the world.

Antitope’s services and technologies enable the selection and creation of antibodies and proteins with reduced potential to be immunogenic in patients. Antitope can also develop manufacturing cell lines for these and other therapeutic antibodies and proteins.

PolyTherics offers product-specific licences for the application of its conjugation and polymer technologies to enable the development of more stable and homogeneous antibody drug conjugates (ADCs) and product candidates with extended in vivo half-life.

Services and technologies Immunogenicity assessment EpiScreen™ is an accurate and sensitive way to assess the potential immunogenicity of proteins and antibodies ex vivo by measuring CD4+ T cell responses, the primary drivers of memory-based immunogenicity. This method has been used across the industry to assess risk at the preclinical stage. Antitope also provides rapid high-throughput in silico analysis of MHC class II binding and T cell epitope location with iTOPE™ and TCED™.

Antibody humanisation and protein deimmunisation Composite Human Antibody™ and Composite Protein™ services are used to create biopharmaceuticals devoid of the T cell epitopes that lead to an

adverse immune response while minimising the loss of antibody affinity or protein activity that can occur with standard protein engineering techniques.

Cell line development High-expressing mammalian cell lines are developed for the production of specific partner antibodies and proteins, including biosimilars, using Composite CHO™, NS0, Sp2/0 or other cell lines. Cell lines suitable for commercial manufacture can be transferred to your own manufacturing facility or directly to your preferred GMP contract manufacturingorganisation.

Antibody drug conjugates PolyTherics has developed its range of novel ThioBridge™ linkers to efficiently conjugate drugs to antibodies to create less heterogeneous ADCs with better stability. Its proprietary technology uses site-specific conjugation to naturally occurring inter-chain disulfides avoiding the need for antibody re-engineering.

Optimisation of pharmacokinetics PolyTherics’ proprietary PEGylation technologies enable polyethylene glycol (PEG) or other polymers to be conjugated to specific sites to extend the in vivo half-life of therapeutic proteins. TheraPEG™ conjugates PEG at disulfide bonds, HiPEG™ to poly-histidine motifs and CyPEG™ to a thiol on a free cysteine. PolyTherics’ has conjugated both linear and branched PEG and its proprietary low-viscosity polymer, PolyPEG™ to a variety of therapeutic proteins.

Contact Information: Abzena plc Tel: +44 (0) 1223 903498 Email: info@abzena.com Web: www.abzena.com

Source R&D

7

Company Profiles

F

ounded in 1987, AMS Biotechnology (AMSBIO) is recognised today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries.

AMSBIO is able to draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation.

Widely acknowledged as an expert in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance organoid and spheroid type screening outcomes from a technological and cost-effective perspective. Custom services include stable cell line production,CRISPR/Cas9 Genome Editing,lentivirus and adenovirus production, largescale protein production and a comprehensive portfolio of antibody services.

Contact Information: AMS Biotechnology (Europe) Limited Tel: +44 (0)1235 828200 Email: info@amsbio.com Web: www.amsbio.co.uk

C

ambridge Research Biochemicals (CRB) offers over 34 years of expertise as a provider of custom peptides and bespoke antibody tools, to Pharmaceutical, Biotechnology and Research Institutes throughout the world. The superior quality of the products and services combined with the complexity and intricacy of the majority of projects undertaken is showcased via customer testimonials and publications.

CRB offers the highest quality custom made polyclonal and monoclonal antibodies, in addition to custom synthesis of peptides of various flavours including stable-isotope, radio-isotope and fluorescently labelled products at the highest level of purity, from milligram to gram scale. Detailed technical consultation on peptide and antibody design is offered and a dedicated customer service team is in place. CRB also offers the most comprehensive range of proprietary dyes for labelling peptides, proteins and antibodies and has a licence in place to perform ‘Click’ labelling of peptides and

8

Source R&D

CRB’s expanded new premises, The Gardner Ratcliffe Building proteins from The Scripps Research Institute.

CRB is a preferred supplier to the MRC and recently relocated and expanded the business, moving to a 10,000 sq ft facility named ‘The Gardner Ratcliffe Building’ after two highly esteemed collaborators. Equipped with brand-new state-of-the-art laboratory equipment and office space, the expansion has allowed CRB to increase production capacity and further enhance the peptide and antibody portfolio.

Contact Information: Cambridge Research Biochemicals Tel: +44 (0) 1642 567180 Email: crbsales@crbdiscovery.com Web: www.crbdiscovery.com

Company Profiles

leading GPEx® cell line expression system, clinical biomanufacturing capabilities and integrated development, analytical and clinical supply services to help you get better products to clinic faster.

C

atalyst + Talent. Catalent’s name combines these ideas.

From drug and biologic development services to delivery technologies to supply solutions, Catalent is the catalyst for your success. With more than 80 years of experience across Rx and consumer markets, the company has the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results.

Catalent develops. With its broad range of expert services Catalent drives faster, more efficient development timelines to help you take more molecules to market and create more effective products.

Catalent delivers. As the world leader in drug delivery innovations, Catalent has a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments.

Catalent supplies. Globally positioned to serve all your manufacturing and commercial packaging needs, Catalent provides integrated solutions to take your product from design, to clinical trial, to plant, and to pharmacy.

Development and analytical solutions Catalent, the world’s No. 1 Formulation and Development partner, leads the industry with laboratory and chamber capacity, operational excellence, on-time delivery of reports and effective regulatory assessment. Its integrated services provide unique partnering efficiencies to ensure advancement of your large- or small-molecule product through development and registration to commercialisation.

Clinical supply services Tailored solutions from a global leader. With over 25 years of clinical trial supply experience, serving more than 4,500 clinical trials, Catalent has the resources and expertise to deliver costeffective and time-sensitive solutions around the world. Whether you are seeking standalone support or a comprehensive package, Catalent has the right solution for you. Its customer-centric project management and integrated solutions will help accelerate your project and provide peace of mind. Clinical expertise and offerings span all facets of clinical trials, including: • Clinical scale manufacturing • Direct global comparator sourcing • Clinical packaging and labelling • Warehousing, distribution, and returns management.

Catalent. More products. Better treatments. Reliably supplied.™ Catalent RP Scherer softgel technologies Catalent is the world leader of softgel drug delivery technologies. As the originator of the RP Scherer softgel rotary die process, Catalent has 80 years of global manufacturing expertise and produces a majority of branded prescription softgel products. Catalent has the breadth and depth of expertise in gelatin/non-gelatin based softgel technologies to solve your toughest drug delivery challenges.

Contact Information: Catalent Pharma Solutions Tel (USA): +1 888 765 8846 Tel (Europe): 00800 88556178 Email: solutions@catalent.com Web: www.catalent.com

Modified release technologies From drug development services to delivery technologies and supply solutions, Catalent is the catalyst for your success. Catalent has the deepest expertise and the most innovative drug delivery technologies to enhance your product performance, including OSDrC® OptiDose™ optimised dosing, Zydis® fastdissolve formulations and OptiMelt™ hot melt extrusion.

Biologics Catalent is your strategic partner for biologic drug development success. The company creates smart, tailored solutions with its novel SMARTag™ ADC Technology, its market Source R&D

9

Company Profiles

E

votec is a drug discovery solutions company providing drug discovery expertise and capabilities to pharmaceutical and biotechnology companies as well as to academic institutions.

Drug discovery solutions are provided in the form of feefor-service work, integrated drug discovery alliances, development partnerships, licensing of innovative drug candidates and consulting arrangements. The company operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, pain, metabolic diseases, oncology, infection and inflammation. By leveraging this expertise, Evotec intends to develop best-in-class and first-inclass differentiated therapeutics on its systematic, unbiased and comprehensive infrastructure.

Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition, the company has existing development partnerships and product candidates both in clinical and preclinical development.

These include partnerships with Boehringer Ingelheim and MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer’s disease.

Evotec is built on integrated drug discovery know-how of 20 years

10 Source R&D

and is a leading player in the drug discovery field. The company’s headquarters are located in Hamburg, Germany. Additional major operating sites exist in Abingdon, UK; Göttingen and Munich, Germany; and South San Francisco and Branford, USA. Evotec has more than 600 employees worldwide.

Evotec’s services Target identification & validation Hit identification Compound management Medicinal chemistry ADME profiling Proteomics and biomarker science Cell and protein production In vitro pharmacology In vivo pharmacology Integrated services Contact information: Evotec (UK) Ltd Tel: +44 (0)1235 861561 Email: info@evotec.com Web: www.evotec.com

Company Profiles

the Power of Now.

TM

The world has changed and pharma now needs to be not just fast, but first. Through our extensive drug development knowledge, we provide access to a wide portfolio of APIs and Intermediates, along with industry-leading technology and services from our state-of-the-art research and manufacturing facilities. CPS delivers world-class Chiral Technology, HPAPIs (including cytotoxics), Steroids and Activated mPEGs.

We also provide integrated full service solutions, including drug substance, pre-formulation and drug product to solve customers’ complicated product development challenges. Partner with us, and we’ll assign you a dedicated project management team to reduce your timelines and improve your ROI. We work smarter because we know you need to get your innovations to market faster.

The power of now

TM

To bring the Power of NowTM into your business, visit www.drreddys-cps.com

Delivering results with Source R&D

11

Company Profiles

I

sogenica discovers antibodies, peptides and other biologics using a suite of state-of-the-art complementary technologies: from library design, fabrication, target validation through to display, selection, screening, characterisation and optimisation of leads. Each project is managed and operated by experts in the field of protein engineering and cell-based methodologies who have gained considerable experience in industry or academia.

Notably, Isogenica is a world leader in the fabrication of novel combinatorial libraries using Colibra™ – its proprietary codon-by-codon enzyme-based library synthesis method.

Using Colibra™, Isogenica is producing the best-in-class next generation of antibody fragment libraries (scFv, VHH and Fab) that can be utilised to rapidly select and develop hits against difficult targets. Its libraries generate products that are defined by clear performance metrics for affinity, bio-manufacturing and ultimately clinical use. These can be accessed on a fee-for-service basis or through licence. Isogenica also operates Colibra™ as a service for custom library manufacture, uniquely providing customers with next-generation sequencing QA/QC procedures to guarantee library quality.

In addition to its antibody capabilities, Isogenica also has extensive experience in protein engineering and peptide selection as a tool for small-molecule drug discovery.

Isogenica’s expertise and proprietary technologies can be accessed through partnerships and licences.

Contact Information: Isogenica Ltd Tel: +44 (0)1799 533680 Email: ajay.mistry@isogenica.com Web: www.isogenica.com

14 July 2015 Cambridge,UK Translating UK scientific excellence into global therapeutic strategies

The Wellcome Trust Conference Centre, Hinxton, Cambridge • A unique UK Translational Research Conference • Keynote addresses by opinion leaders • An interactive case study based programme • Practical insights on funding and collaborations in translational research projects • A networking platform for academia and businesses onhelix.com

12 Source R&D

Our translational research conference

Company Profiles

Putting Science First . . .

N

ew England Biolabs (NEB) is a world leader in the discovery, production, and supply of reagents for the life sciences. For 40 years, NEB has been dedicated to the advancement of science, and its commitment to meeting the needs of the scientific community by providing exceptional product quality and technical support has never wavered.

NEB is passionate about science and is driven to advance the frontiers of knowledge. As a collaborator, rather than just a vendor, NEB is committed to understanding customers’ needs and developing products to address them.

It aims to support its customers’ research as though it were its own. As such, NEB is at the forefront of providing the solutions and tools necessary to accelerate scientific research and drive new discoveries.

NEB’s state-of-the-art headquarters, located in Ipswich, MA, USA, is ISO 9001, ISO 13485, ISO 14001, and LEED certified. The NEB facilities include a modern fermentation centre and laboratories for production, quality control, product development, and basic research. With a depth of experience in recombinant technologies, many of its products are manufactured on a large scale to stringent specifications, resulting in higher quality with proven lot-to-lot consistency.

Advancement of scientific research is at the core of NEB’s corporate philosophy. NEB researchers have published over 875 peer-reviewed articles to date, in areas including next-generation sequencing, epigenetics, glycobiology, RNA analysis, protein expression, cellular analysis, restriction enzymes, and polymerases. NEB also focuses on subjects outside of its commercial interests—NEB’s Parasitology Research Division is one example of this.

Markets served NEB serves life science researchers in industry, government, and academia. Across these different market segments, NEB’s reagents are used, both directly and via supply to third-party collaborators, in a variety of applications, including DNA cloning, PCR, epigenetics, RNA analysis, protein expression, purification and analysis, sample preparation for nextgeneration sequencing, and cellular analysis.

NEB’s reagents are available worldwide through its network of exclusive distributors, agents, and subsidiaries, the latter being located in Canada, China, France, Germany, Japan, Singapore, and the UK.

NEB solutions Through its NEBsolutions team, NEB has extended its expertise in enzymology and reagent manufacturing into new and emerging markets, such as molecular diagnostics. Scientific expertise, rapid response times, custom product formulations, and private labeling are just a few of the ways this team assists its customers in reducing their time to market.

NEB’s experienced team of research and production scientists directly assist in the development of its customers’ reagents for their specific application or instrument platform. The NEBsolutions team will work

Partner with the NEBsolutions team, and together redefine the traditional OEM relationship: view the video at neb.com

Learn which partnering opportunities NEB is actively seeking, and how partnership can bolster your pipeline: view the video at neb.com. to optimise reagent formulation, function, and manufacturing process.

This often results in reduction of manufacturing costs and the amount of enzyme required, thus lowering the customers’ overall costs.

Using its extensive experience in both business and science, the NEBsolutions team excels at meeting aggressive timelines and offers a rapid lead-time for most custom requests. This includes leveraging the capabilities of the entire company to help customers achieve their goals during all stages of a product’s lifecycle.

NEB solutions is your solution With over 20 years of experience in the development and supply of reagents for OEM customers, when you select NEB as your partner, you achieve more than simply sourcing high-quality reagents and production capabilities: you become a part of the team, and NEB, in turn, becomes a part of yours. Bring NEB your product request or your problem, and experience the expertise, responsiveness, flexibility, and quality that NEBsolutions can provide.

Contact Information: New England Biolabs Tel: +1 978 927 5054 Email: NEBsolutions@neb.com Website: www.neb.com/neb-solutions Source R&D

13

Company Profiles

P

athology Diagnostics Ltd is an independent GCLP-accredited histopathology research organisation delivering high-quality tissue laboratory & diagnostics services to industry Research & Development scientists engaged in drug and biomarker development.

Specialising in the provision of clinical diagnostics and quantitative image analysis on human tissues for studies ranging from early discovery to clinical trials, Pathology Diagnostics offers a range of services from traditional histopathology techniques to advanced digital pathology, whole slide scanning, central biorepository services and quantitative image analysis of biomarkers.

Pathology Diagnostics comprises of a team of expert board-certified pathologists and trained scientists / technical

staff with specific experience of particular project needs, including target discovery, preclinical models, clinical trials and tissue-based biomarker testing.

The company can provide a range of services, including: expert tissue diagnostic analysis of human clinical tissue samples by medical pathologists; high-resolution image capture and morphometric image analyses including quantitative image analysis of pharmacodynamic biomarker IHC assays, project management advice by key consultants, tissue laboratory processing and immunohistochemistry.

Its core strengths are its breadth of experience - from molecular biology to human diagnostic pathology, and its ability to interact with scientists and clinicians to support the development of scientific discoveries into new therapeutics and biomarkers for the clinic.

Contact Information: Pathology Diagnostics Ltd Tel: +44 (0)1223 851354 Email: info@pathologydiagnostics.com Web: www.pathologydiagnostics.com

P

roSynth Limited is engaged in all aspects of organic synthesis.

For over 22 years the company has provided a wide range of clients with high-quality intermediates, and bespoke services in process development and custom synthesis. It responds confidentially and accurately to various individual requirements, providing pragmatic solutions in a timely and cost-effective manner.

Operating from purpose-built laboratories close to Cambridge, ProSynth is small enough to care about, and large enough to cope with, projects from 10 grams to 100 kilos and beyond. It holds in excess of one hundred confidentiality agreements and has more than 18,000 procedures documented on its internal database.

The materials produced are examined by a broad range of analytical techniques, including HPLC (chiral where necessary), GC, MS, IR, UV and magnetic resonance spectra. Despatches, whether local or global, are made by qualified shippers and always carry a Certificate of Analysis and Material Safety Data Sheet.

ProSynth’s project management has been highly commended by clients, and routinely includes written weekly updates and a

14 Source R&D

comprehensive campaign report on completion.

ProSynth is the synthesis partner to help advance your ideas from a sketch in a notebook, through small-scale trials to proof of concept and beyond. The company would be delighted to discuss your requirements.

Contact Information: Prosynth Limited Tel: +44 (0)1787 883320 Email: info@prosynth.com Web: www.prosynth.com

Company Profiles Contact Information

CRO, CMO and service provider member companies 42 Technology Ltd

Ariana Pharmaceuticals

Tel: +44 (0)1480 302700

AMS Biotechnology (Europe) Limited

Tel: +33 1 44 37 17 00

Cambridge Bioscience Limited

Email: answers@42technology.com

Tel: +44 (0)1235 828200

Web: www.arianapharma.com

Tel: +44 (0)1223 316855

Web: www.42technology.com

Email: info@amsbio.com

A4Pbio

Web: www.amsbio.co.uk

Email: support@bioscience.co.uk

Asterand UK

Web: www.bioscience.co.uk

Tel: +44 (0)1763 211600

Tel: +44(0) 1304 249106

AnaBioTec

Email: info@asterand.com

Cambridge Cell Networks Ltd (CCNet Ltd)

Email: info@a4pbio.com

Tel: + 32 92415640

Web: www.asterand.com

Tel: +44 (0)1223 703 137

Web: www.a4pbio.com

Email: anabiotec@anabiotec.com Web: www.anabiotec.com

Abcam plc Tel: +44 (0)1223 696000 Email: corporate@abcam.com

Banook Group

Email: info@camcellnet.com Web: www.camcellnet.com

Tel: +07500862078

APL

E: fabien.dufraisse@banook-ms.com

Tel: +46 10 447 96 00

Web: www.banook-ci.com

Tel: +44 (0)1223 804 260

Email: mattias.nystrom@apl.se

Web: www.abcam.com

Web: www.apl.se

Abcodia Ltd

Aptiv Solutions

Tel: 07747 765069

Tel: +44 (0)1628 643920

Email: julie.barnes@abcodia.com

Web: www.aptivsolutions.com

Web: www.abcodia.com

Aptus Clinical Limited

Abeterno Ltd

Tel: +44 (0)1625 238662

Cambridge Epigenetix Limited

Beckman Coulter Genomics

Email: info@cegx.co.uk

Tel: +44 (0)1279 873837

Cambridge Research Biochemicals

Web: www.cogenics.com

Biocair International Ltd Tel: +44 (0)1223 703306

Web: www.cambridge-epigenetix.com

Tel: +44 (0)1642 567180 Email: crbsales@crbdiscovery.com Web: www.crbdiscovery.com

Email: info@aptusclinical.com

Email: cambridge@biocair.com

Web: www.aptusclinical.com

Web: www.biocair.com

Aqix Ltd

Tel: +44 (0)1223 423 413

Tel: +44 (0)20 7554 5852

BioFocus (Charles River Early Discovery)

Email: info@aqix.com

Tel: +44 (0)1799 533500

Web: www.cantabbio.com

Web: www.aqix.com

Email: biofocus@glpg.com

Carbogen Amcis AG

Abzena plc

Arecor Limited

Web: www.biofocus.com

Tel: 0041 61 935 5353

Tel: +44 (0)1223 903498

Tel: +44 (0)1223 426060

Bionow

Email: info@abzena.com

Email: info@arecor.com

Web: www.abzena.com

Web: www.arecor.com

Tel: +44 (0)1223 804055

ABS Laboratories Ltd Tel: +44 (0)1707 358666 Email: abslabs@biopark.org.uk Web: www.abslabs.com

Amies Innovation Ltd Tel: +44 (0)1246 568046 Email: jane@amiesplastics.co.uk Web: www.amiesinnovation.co.uk

Argenta Discovery (Charles River Early Discovery) Tel: +44 (0)1279 645645 Email: argenta@glgp.com

Cantab Biopharmaceuticals Ltd Email: info@cantabbio.com

Email: info@carbogen-amcis.com Web: www.carbogen-amcis.com

Tel: 07714 168020 Email: info@bionow.co.uk Web: www.bionow.co.uk

Catalent Pharma Solutions Tel (USA): +1 888 765 8846

Biopharma Technology Ltd

Tel (Europe): 00800 88556178

Tel: +44 (0)1962 841 092

Email: solutions@catalent.com

Email: btl@biopharma.co.uk

Web: www.catalent.com

Charles River Laboratories Early Discovery

Amphora Research Systems

Web: www.argentadiscovery.com

Web: www.biopharma.co.uk

Argon Design Ltd

Bio-Rad AbD Serotec Ltd

Tel: 0845 2300160

Tel: +44 (0)1223 422 355

Tel: +44 (0)1865 852700

Tel: +44 (0)1279 645645

Email: info@amphora-research.com

Email: info@argondesign.com

Email: abd_sales_uk@bio-rad.com

Email: admin@criver.com

Web: www.amphora-research.com

Web: www.argondesign.com

Web: www.abdserotec.com

Web: www.criver.com

Entries highlighted in red are featured in the Company Profiles section (pages 7-14)

(Argenta Discovery/BioFocus)

Source R&D

15

Contact Information Company Profiles

Cisbio Bioassays

Epistem Ltd

Illumina Cambridge Ltd

Tel: +33 (0)4 66 79 67 05

Tel: +44 (0)161 606 7258

Tel: +44 (0)1799 532300

Pathology Diagnostics Ltd

Email: bioassays@cisbio.com

Email: info@epistem.co.uk

Email: info@illumina.com

Tel: +44 (0)1223 851 354

Web: www.htrf.com

Web: www.epistem.co.uk

Web: www.illumina.com

E: info@pathologydiagnostics.com

ClinicaGeno Ltd.

Essen BioScience Ltd

Imanova Ltd

Tel: +447779099957

Tel: +44 (0)1707 358685

Tel: +44 (0)20 8008 6000

Email: admin@clinicageno.com

Email: ics@essenbio.com

Email: enquiries@imanova.co.uk

Web: www.clinicageno.com

Web: http://essenbioscience.com

Web: www.imanova.co.uk

Cresset BioMolecular Discovery Ltd

Eurofins Panlabs

Integrated Medicines Ltd

Tel: +44 (0)1223 858890

Email: PanlabsPharmacology@

Email: info@cresset-group.com

eurofins.com

Web: www.cresset-group.com

Web: www.eurofinspanlabs.com

Cyclofluidic Ltd Tel: +44 (0)1707 358673 Web: www.cyclofluidic.co.uk

Cytocell Limited Tel: +44 (0)1223 294048

Tel: +44 (0)1494 868557

Europa Bioproducts Ltd Tel: +44 (0)1353 721118 Email: info@europa-bioproducts.com

Tel: +44 (0)1954 718122

Intertek Melbourn Tel: +44 (0)1763 261648 Email: info@melbournscientific.com

Evotec (UK) Ltd Email: info@evotec.com

Email: contact@pharmidex.com Web: www.pharmidex.com

Pharmorphix Tel: +44 (0)1223 425105 Email: info@sial.com Web: www.safcglobal.com

Physiomics plc Tel: +44 (0)1799 533680

Tel: +44 (0)1235 861561

Tel: 0870 240 5978

Web: www.melbournscientific.com

Isogenica Ltd

Web: www.cytocell.com

Pharmidex Pharmaceutical Services Ltd

Web: www.integratedmedicines.co.uk

Web: www.europa-bioproducts.com

Email: probes@cytocell.com

Web: www.pathologydiagnostics.com

Email: ajay.mistry@isogenica.com

Tel: +44 (0)1865 784980 Email: info@physiomics-plc.com Web: www.physiomics-plc.com

Web: www.isogenica.com

Web: www.evotec.com

KWS BioTest Ltd

Population Genetics Technologies Ltd

Tel: +44 (0)1223 497113

Fahy Gurteen Laboratories

Tel: +44 (0)117 9287886

Tel: +44 (0)1223 497357

Email: enquiries@definigen.com

Tel: +44 (0)1223 20 50 40

Email: info@kwsbiotest.co.uk

Email: info@populationgenetics.com

Web: www.definigen.com

Email: contact@fglabs.com

Web: www.kwsbiotest.co.uk

Web: www.populationgenetics.com

deltaDOT Limited

Web: www.fglabs.com

LGC

Tel: +44 (0)207 691 2075

Fisher BioServices

Tel: +44 (0)1992 470 757

PRECOS Ltd (a Crown Bioscience Company)

Email: info@deltadot.com

Tel: +44 (0)1279 713320

Email: info.uk@lgcgenomics.com

Tel: 0870 166 6234

Web: www.deltadot.com

Web: www.fisherbioservices.com

Web: www.lgcgenomics.com

E: Vicky.Murray-tait@precos.co.uk

Domainex Ltd

Fisher Scientific UK

Lonza Biologics Plc

Tel: +44 (0)1223 743170

Tel: +44 (0)1509 231166

Tel: +44 (0)1753 777000

Promega UK Ltd

Email: enquiries@domainex.co.uk

Web: www.fisher.co.uk

Email: custom@lonza.com

Tele: 023 8076 0225

FluidX Ltd

Web: www.lonzagroup.com

Email: ukcustserve@promega.com

Dr Reddy’s

Email: sales@fluidx.co.uk

Tel: +44 (0)1223 728010

Web: www.fluidx.co.uk

New England Biolabs (UK) Ltd

DefiniGEN

Web: www.domainex.co.uk

Email: cjones@drreddys.com

Web: www.crownbio.com

Web: www.promega.com

Prosarix Ltd

Tel: +44 (0)1462 420616

Tel: +44 (0)1223 870400

Email: info@uk.neb.com

Email: contact@prosarix.com

Web: www.gehealthcare.com/uken/

Web: www.neb.uk.com

Web: www.prosarix.com

Horizon Discovery Group plc

Novus Biologicals Ltd

Prosynth Ltd

Tel: +44 (0)1223 426 001

Tel: +44 (0)1787 883320

products.com

Tel: +44 (0)1223 655580

Email: novus@nobusbio.com

Email: info@prosynth.com

Web: www.dundeecellproducts.com

Web: www.horizondiscovery.com

Web: www.novusbio.com

Web: www.prosynth.com

Eagle Genomics Ltd

Huntingdon Life Sciences

OctoPlus N.V.

QCTR Ltd

Tel: +44 (0)1223 654481

Tel: +44 (0)1480 892000

Tel:+31 71 524 4044

Tel: +44 (0)1786 270400

Email: info@eaglegenomics.com

E: strat.dev@ukorg.huntingdon.com

Email: vanderhoeven@octoplus.nl

Email: info@qctr.co.uk

Web: www.eaglegenomics.com

Web: www.huntingdon.com

Web: www.octoplus.nl

Web: www.qctr.co.uk

Web: www.drreddys.com

GE Healthcare Tel: 08702 407575

Dundee Cell Products Ltd Tel: +44 (0)1382 220749 Email: customerservices@dundeecell-

16 Source R&D

Contact Information Company ProďŹ les Quintiles

Selcia Ltd

Sigma-Aldrich

SYNthesis med chem

E: martin.gouldstone@quintiles.com

Tel: +44 (0)1277 367000

Tel: +44 (0)1440 767000

Tel: +44 (0)1223 804051

Web: www.quintiles.com

Email: contact@selcia.com.

E: customerservice@europe.sial.com

Email: enquiries@synmedchem.com

Web: www.selcia.com

Web: www.sigma-aldrich.com

Web: www.synmedchem.com

Stem Cell Sciences (UK) Ltd

TwistDx Ltd

Tel: +44 (0)1159 749000

Sera Laboratories International Ltd

Email: enquiries@quotientclinical.com

Tel: +44 (0)1444 250010

Tel: +44 (0)1223 499160

Email: info@twistdx.co.uk

Web: www.quotientclinical.co.uk

Web: www.seralab.co.uk

Web: www.stemcellsinc.com

Web: www.twistdx.co.uk

SEEK (formerly PepTcell Limited)

SGS M-Scan Ltd

Sygnature Discovery Ltd

Vetter Pharma International GmbH

Tel: (0)118 989 6940

Tel: +44 (0)1159 415401

Tel: +49 (0)751 3700 0

Tel: +44 (0)20 7153 6570

Email: services.ltd@m-scan.com

Email: info@sygnaturediscovery.com

Email: info@vetter-pharma.com

Web: www.seekacure.com

Web: www.m-scan.com

Web: www.sygnaturediscovery.com

Web: www.vetter-pharma.com

Quotient Clinical Ltd

Tel: +44 (0)1223 496700

CRO, CMO and service provider member companies Agenda 1 Analytical Services

Euprotec Limited

Intertek MSG

Perfectus Biomedical Ltd

Tel: +44 (0)161 820 3620

Tel: +44 (0)1642 435766

Tel: +44 (0)7841 342904

Email: info@euprotec.com

Email: msgenquiry@intertek.com

Email: sam@perfectus-medical.com

Web: www.euprotec.com

Web: www.intertek.com

Web: www.perfectus-medical.com

Gaea Clinical Ltd

Intertek

Protein

Tel: +44 (0)1625 413900

Pharmaceutical Services

Technologies Ltd

Tel: +44 (0)1625 238610

Email: ngg@gaea.co.uk

Tel: +44 (0)161 721 5247

Tel: +44 (0)161 226 2366

Email: elizabeth Thomas@Alderley

Web: www.gaea.co.uk

Email: asgenquiries@intertek.com

Email: info@protein-technologies.com

Hematogenix

Web: www.intertek.com/pharmaceu-

Web: www.protein-technologies.com

Tel: +44 (0)1708 4688700

tical/asg

Research Nurses Ltd

Orla Protein

Tel: +44 (0)1625 662944

Technologies Ltd

Email: info@researchnurses.co

Tel: +44 (0)1274 326073 Email: isiragher@agenda1.co.uk Web: www.agenda1.co.uk

Alderley Analytical Ltd

analytical.co.uk Web: www.alderleyanalytical.co.uk/

Almac Group

Email: Halmasri@hematogenix.com

Tel: 028 3833 2200 Email: susan.beattie@almacgroup.com

Web: www.hematogenix.com

Web: www.researchnurses.co

Web: www.almacgroup.com

High Force Research Ltd

Tel: +44 (0)191 231 3127

Aptus Clinical

Tel: +44 (0)191 3779098

Email: dale.athey@orlaproteins.com

Tomorrows

Tel: +44 (0)1625 238662

E: enquiries@highforceresearch.com

Web: www.orlaproteins.com

Medicines Limited

Email: anita@aptusclinical.com

Web: www.highforceresearch.com

Web: www.aptusclinical.com

Illingworth Research Ltd Cobra Biomanufacturing plc Tel: +44 (0)1782 714181 Email: philridley-smith@cobrabio.com

Patheon Tel: +44 (0)1793 524411

Tel: +44 (0)1625 617447 Email: susie.berrill@patheon.com Email: info@illingworthresearch.com Web: www.illingworthresearch.com

Web: www.patheon.com

Tel: +44 (0)1925 607125 Email: dr.cj.nolan@tomorrows medicines.com Web: https://yourtreatment choices.com

Intertek Clinical Research Services

Peakdale

Unilabs (York

Molecular Ltd

Bioanalytical Laboratories)

Tel: +44 (0)161 232 4690

Tel: +44 (0)1298 816 700

Tel: +44 (0)1904 686060

Email: info@cyprotex.com

Email: pal.mayuranathan@intertek.com

Email: sales@peakdale.co.uk

Email: info@yorkbio.com

Web: www.cyprotex.com

Web: www.intertek.com/4Front

Web: www.peakdale.com

Web: www.york-bio.com

Web: www.cobrabio.com

Cyprotex plc Tel: +44 (0)1625 505 100

Source R&D

17

Contact Information Company Profiles

Additional CRO, CMO and service provider companies ACM Global

Cica Biomedical Ltd

Intelligent Pharma Limited

Phasefocus Ltd

Tel: +44 (0)1904 699400

Tel: +44 (0)1423 799091

Tel: +44 (0)191 478 8120

Tel: +44 (0)114 2866377

Web: www.acmgloballab.com

Email: info@cica-biomedical.com

Web: www.intelligentpharma.co.uk

Email: enquiries@phasefocus.com

Web: www.cica-biomedical.com

Web: www.phasefocus.com

Keane Analytical Ltd

Acumen Pharmaceutical Services Ltd

Drew Scientific Co Limited

Tel: +44 (0)161 877 5300

Tel: +44 (0)1229 432089

Email: wayne.griffin@acumenpharma.

Email: products@drew-scientific.com

co.uk

Web: www.drew-scientific.com

Web: www.acumenpharma.co.uk

Edwards Analytical

Tel: +44 (0)1434 672542 Web: www.keane-analytical.co.uk

Quay Pharmaceuticals

Lab M Ltd

Email: enquiries@quaypharma.com

Tel: +44 (0)161 797 5729 Email: info@labm.com Web: www.labm.com

Tel: +44 (0)1244 837000 Web: www.quaypharma.com

Recipharm

AF ChemPharm Limited

Tel: +44 (0)1325 327315

Tel: +44 (0)114 3277279

Email: john@edwards-analytical.com

LPD Laboratory Services Ltd

Email: iain.martin@recipharm.com

Email: a.fallah@afchempharm.co.uk

Web: www.edwards-analytical.com

Tel: +44 (0)1254 676074 Email: stephen.jenkins@lpdlabservices.co.uk Web: www.lpdlabservices.co.uk

Web: www.recipharm.com

Web: www.afchempharm.co.uk

ePitope Informatics Ltd

Alpha Biolaboratories

Tel: +44 (0)1434 609962

Tel: +44 (0)845 50 50 001

Email: glenn.major@epitope-informat-

Email: info@alphabiolabs.co.uk Web: www.alphabiolabs.com

AMRI UK Tel: +44 (0)1352 717100 Email: info@amriglobal.com Web: www.amriglobal.com

Applied Cytometry Systems Tel: +44 (0)1909 547210 Email: customersupport@appliedcytometry.com Web: www.appliedcytometry.com

BioInnovel Ltd Tel: +44 90)191 516 6542

BioServ UK Limited

Simcyp Ltd Tel: +44 (0)114 2922322 Web: www.simcyp.com

ics.com

M & A Pharmachem

Web: www.epitope-informatics.com

Tel: +44 (0)1942 816184 Web: www.mapharmachem.co.uk

Smerud Medical Research UK Ltd

Medicines Evaluation Unit

Tel: +44 (0)161 870 8127 Web: www.smerud.com

Web: www.eurogentec.com

Tel: +44 (0)161 946 4050 Email: enquiries@meu.org.uk Web: www.meu.org.uk

Fujifilm Diosynth Biotechnologies

National Genetics Reference Laboratory

01565 733 772

Tel: +44 (0)1642 363511

Tel: +44 (0)161 276 8703 Web: www.ngrl.org.uk

Web: www.theclinicaltrialcompany.com

Eurogentec Tel: +44 (0)1794 511411 Email: g.mcinnes@eurogentec.com

Email: enquiries@fujifilmdb.com Web: www.fujifilmdiosynth.com

Geneius Laboratories Ltd Tel: +44 (0)191 243 0871 Email: jerry.barnes@geneiuslabs.com Web: www.geneiuslabs.co.uk

Email: joanna.vlahop@bioinnovel.com Web: www.bioinnovel.com

Tel: +44 (0)161 342 6271

Hall Analytical Laboratories Ltd Tel: +44 (0)161 286 7889

Tel: +44 (0)114 224 2235

Email: malcolm@hallanalytical.co.uk

Email: enquiries@bioservuk.co.uk

Web: www.hallanalytical.co.uk

Web: www.bioservuk.com

CARBOGEN AMCIS Ltd

ICON Development Solutions

Tel: +44 (0)161 2233344

Tel: +44 (0)1628 496326

E: ian.burley@carbogen-amcis.com

Email: stephen.rousseau@iconplc.com

NewChem Technologies Tel: +44 (0)191 375 7294 E: sales@newchemtechnologies.com Web: www.newchemtechnologies.com

The Clinical Trial Company Ltd (TCTC) E: info@theclinicaltrialcompany.co.uk

UK Biobank Tel: +44 (0)161 475 5360 Email: enquiries@ukbiobank.ac.uk Web: www.ukbiobank.ac.uk

Newtec Laboratories (Eurofins)

UK Biocentre

Tel: +44 (0)1642 370321 Email: sales@eurofins.co.uk Web: www.eurofins.co.uk

Email: info@ukbiocentre.com

Onyx Scientific Ltd

Universal Products Ltd

Tel: +44 (0)191 516 6516 Email: tonyflinn@onyx-scientific.com Web: www.onyx-scientific.com

Tel: +44 (0)1772 685777

Tel: +44 (0)161 475 5377 Web: www.ukbiocentre.com

Web: www.universal-laboratories.co.uk

Vickers Laboratories Ltd Parexel Tel: +44 (0)114 225 1000 Email: info@parexel.com Web: www.parexel.com

Tel: +44 (0)113 236 2811 Email: info@viclabs.co.uk

Web: www.carbogen-amcis.com

Web: www.iconplc.com

Centre for Process Innovation

Insight Chemical Solutions Ltd

Tel: +44 (0)1642 442481

Tel: +44 (0)151 795 4193 Web: www.insightchemicalsolutions.

Tel: +44 (0)151 670 9090 Email: enquiries@pharmapacuk.com

Tel: +44 (0)1904 561592

Email: chris.dowle@uk-cpi.com Web: www.uk-cpi.com

co.uk

Web: www.pharmapacuk.com

Web: www.york-bio.com

18 Source R&D

Pharmapac UK Ltd

Web: www.viclabs.co.uk

Yorkshire Bioscience Ltd Email: info@york-bio.com

Company Profiles

Bionow is an award-winning specialist business development and services company serving the biomedical sector across the North of England. Our mission is to provide the tools and support for LJŽƵƌ ŽƌŐĂŶŝƐĂƟŽŶ ƚŽ ďĞĐŽŵĞ ĂŵŽŶŐƐƚ ƚŚĞ ŵŽƐƚ ĐŽŵƉĞƟƟǀĞ ŝŶ ƚŚĞ industry, through our range of specialist products and services

Features of Bionow membership include access to industryrenowned awards and conferences, mentoring and training, a ƐƉĞĐŝĂůŝƐƚ ƉƌŽĐƵƌĞŵĞŶƚ ƐĐŚĞŵĞ ǁŝƚŚ ƐŝŐŶŝĮĐĂŶƚ ĐŽƐƚ ƐĂǀŝŶŐƐ͕ discounted rates on general business products and services, dedicated business support programmes, online networking and access to a vibrant network of businesses

To speak to us about membership and the savings that can be achieved, please contact Dr Diane Cresswell on 07766 991 932 or email us: info@bionow.co.uk www.bionow.co.uk Source R&D

19

Company Profiles

analytical services

leading analytical expertise. more products.

Whether you require analytical, physical, biological or microbiological techniques, we help you create a faster path to regulatory approval and market.

BROAD CAPABILITIES, TAILORED SOLUTIONS From characterization to method development to viral clearance and lot testing, we can tailor an analytical program to fit your needs and timelines.

LOCAL EXPERTISE, GLOBAL REACH Our facilities in the US, UK and Germany provide local expertise and worldwide coverage.

LARGE & SMALL MOLECULE SERVICES From rapid testing of early candidates to regulatory submission, we can support your toughest molecules.

WORLD’S LARGEST STABILITY CAPACITY & PROVEN EXPERTISE

© 2012 Catalent Pharma Solutions. All rights reserved.

We have 70,000+ cu.ft. of capacity across the US and EU supported by 300+ degreed scientists and professionals, including 50+ PhD’s.

20 Source R&D

Every molecule has a challenge.

We have a solution.

Call: + 1 888 SOLUTION (765 8846) Europe: 00800 88 55 6178 Email: solutions@catalent.com Visit: www.catalent.com

DEVELOPMENT

DELIVERY

SUPPLY